Emily Godfrey
Family Medicine · Seattle, WANPI 1437260551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,308 of the $20,400 with a category attached, or 99.6%. Organon accounts for 94.8% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $850.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$19K
- Merck$1K
- Bayer$41
Across 2 payments — averaging $38,593 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$77K
What the payments were for
- Speaking & faculty fees$20,308100%
- Travel & lodging$270%
- Food & beverage$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$16,125
How this compares
$20,400 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 12 | $1,021 |
| Atorvastatin Calcium | 41 | $441 |
| Pregabalin | 19 | $187 |
| Levothyroxine Sodium | 14 | $114 |
| Fluoxetine Hcl | 15 | $113 |
| Lisinopril | 14 | $89 |
| Tamsulosin Hcl | 12 | $77 |
| Amlodipine Besylate | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Seattle
- Kevin HatfieldSeattle$527K
- Robert McIntyreSeattle$107K
- Ian BennettSeattle$41K
- Betsy BrownSeattle$23K
- Matthew PowellSeattle$11K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.